{"transactions":[{"id":4639723,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":1559,"kind":"organization","name":"Opaleye Management Inc.","position":1,"cik":"0001595855","reported_name":"Opaleye Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2026-10-13T21:45:03.000Z","date":"2026-10-12","kind":"purchase","planned":false,"acquired":true,"shares":7215,"price":2.02,"value":14574.3,"ownership":{"direct":false,"nature":"By Opaleye, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents securities owned directly by Opaleye, L.P. (the \"Fund\"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2873289,"source":{"system":"sec-edgar","filing":"0001493152-26-046899","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1595855/000149315226046899/ownership.xml","form_type":"4"}},{"id":4639722,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":1559,"kind":"organization","name":"Opaleye Management Inc.","position":1,"cik":"0001595855","reported_name":"Opaleye Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2026-10-13T21:45:03.000Z","date":"2026-10-09","kind":"purchase","planned":false,"acquired":true,"shares":5340,"price":2.0446,"value":10918.164,"ownership":{"direct":false,"nature":"By Opaleye, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.03 to $2.05. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents securities owned directly by Opaleye, L.P. (the \"Fund\"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2866074,"source":{"system":"sec-edgar","filing":"0001493152-26-046899","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1595855/000149315226046899/ownership.xml","form_type":"4"}},{"id":4639721,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":1559,"kind":"organization","name":"Opaleye Management Inc.","position":1,"cik":"0001595855","reported_name":"Opaleye Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2026-10-13T21:45:03.000Z","date":"2026-10-08","kind":"purchase","planned":false,"acquired":true,"shares":2077,"price":2.0175,"value":4190.3475,"ownership":{"direct":false,"nature":"By Opaleye, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents securities owned directly by Opaleye, L.P. (the \"Fund\"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2860734,"source":{"system":"sec-edgar","filing":"0001493152-26-046899","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1595855/000149315226046899/ownership.xml","form_type":"4"}},{"id":4631212,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":1559,"kind":"organization","name":"Opaleye Management Inc.","position":1,"cik":"0001595855","reported_name":"Opaleye Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2026-10-05T22:46:05.000Z","date":"2026-10-05","kind":"purchase","planned":false,"acquired":true,"shares":1694,"price":2.06,"value":3489.64,"ownership":{"direct":false,"nature":"By Opaleye, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents securities owned directly by Opaleye, L.P. (the \"Fund\"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2858657,"source":{"system":"sec-edgar","filing":"0001493152-26-045809","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1595855/000149315226045809/ownership.xml","form_type":"4"}},{"id":4631211,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":1559,"kind":"organization","name":"Opaleye Management Inc.","position":1,"cik":"0001595855","reported_name":"Opaleye Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2026-10-05T22:46:05.000Z","date":"2026-10-02","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":2.0684,"value":41368.0,"ownership":{"direct":false,"nature":"By Opaleye, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.03 to $2.07. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents securities owned directly by Opaleye, L.P. (the \"Fund\"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2856963,"source":{"system":"sec-edgar","filing":"0001493152-26-045809","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1595855/000149315226045809/ownership.xml","form_type":"4"}},{"id":4631210,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":1559,"kind":"organization","name":"Opaleye Management Inc.","position":1,"cik":"0001595855","reported_name":"Opaleye Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2026-10-05T22:46:05.000Z","date":"2026-10-01","kind":"purchase","planned":false,"acquired":true,"shares":38796,"price":2.0353,"value":78961.4988,"ownership":{"direct":false,"nature":"By Opaleye, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.00 to $2.04. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents securities owned directly by Opaleye, L.P. (the \"Fund\"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2836963,"source":{"system":"sec-edgar","filing":"0001493152-26-045809","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1595855/000149315226045809/ownership.xml","form_type":"4"}},{"id":4634866,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":1559,"kind":"organization","name":"Opaleye Management Inc.","position":1,"cik":"0001595855","reported_name":"Opaleye Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2026-10-02T00:30:30.000Z","date":"2026-09-29","kind":"purchase","planned":false,"acquired":true,"shares":7849,"price":2.09,"value":16404.41,"ownership":{"direct":false,"nature":"By Opaleye, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents securities owned directly by Opaleye, L.P. (the \"Fund\"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2798167,"source":{"system":"sec-edgar","filing":"0001493152-26-045358","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000149315226045358/ownership.xml","form_type":"4"}},{"id":4634863,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":1559,"kind":"organization","name":"Opaleye Management Inc.","position":1,"cik":"0001595855","reported_name":"Opaleye Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2026-10-02T00:05:26.000Z","date":"2026-09-23","kind":"purchase","planned":false,"acquired":true,"shares":5318,"price":2.1,"value":11167.8,"ownership":{"direct":false,"nature":"By Opaleye, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents securities owned directly by Opaleye, L.P. (the \"Fund\"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2790318,"source":{"system":"sec-edgar","filing":"0001493152-26-045347","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000149315226045347/ownership.xml","form_type":"4/A","original_submission_date":"2026-09-23"}},{"id":4634862,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":1559,"kind":"organization","name":"Opaleye Management Inc.","position":1,"cik":"0001595855","reported_name":"Opaleye Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2026-10-02T00:05:26.000Z","date":"2026-09-21","kind":"purchase","planned":false,"acquired":true,"shares":9771,"price":2.1,"value":20519.1,"ownership":{"direct":false,"nature":"By Opaleye, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents securities owned directly by Opaleye, L.P. (the \"Fund\"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2785000,"source":{"system":"sec-edgar","filing":"0001493152-26-045347","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000149315226045347/ownership.xml","form_type":"4/A","original_submission_date":"2026-09-23"}},{"id":4625715,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":1559,"kind":"organization","name":"Opaleye Management Inc.","position":1,"cik":"0001595855","reported_name":"Opaleye Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2026-09-23T22:19:25.000Z","date":"2026-09-23","kind":"purchase","planned":false,"acquired":true,"shares":5318,"price":2.1,"value":11167.8,"ownership":{"direct":false,"nature":"By Opaleye, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents securities owned directly by Opaleye, L.P. (the \"Fund\"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2855318,"source":{"system":"sec-edgar","filing":"0001493152-26-043996","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1595855/000149315226043996/ownership.xml","form_type":"4"}},{"id":4625714,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":1559,"kind":"organization","name":"Opaleye Management Inc.","position":1,"cik":"0001595855","reported_name":"Opaleye Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2026-09-23T22:19:25.000Z","date":"2026-09-21","kind":"purchase","planned":false,"acquired":true,"shares":9771,"price":2.1,"value":20519.1,"ownership":{"direct":false,"nature":"By Opaleye, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents securities owned directly by Opaleye, L.P. (the \"Fund\"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2850000,"source":{"system":"sec-edgar","filing":"0001493152-26-043996","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1595855/000149315226043996/ownership.xml","form_type":"4"}},{"id":4623265,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":69511,"kind":"person","name":"NEUGEBOREN EDWARD","position":1,"cik":"0001320873","reported_name":"NEUGEBOREN EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-21T20:22:31.000Z","date":"2026-09-17","kind":"grant","planned":false,"acquired":true,"shares":12200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments over a 12-month period, subject to the Reporting Person's continuous service as of each vesting date."}],"balance_after":12200,"derivative":{"exercise_price":2.13,"expiration_date":"2036-09-16","underlying":"Common Stock","underlying_shares":12200},"source":{"system":"sec-edgar","filing":"0001140361-26-037246","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126037246/form4.xml","form_type":"4"}},{"id":4623247,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":69510,"kind":"person","name":"DAVIS A BRIAN","position":1,"cik":"0001184432","reported_name":"DAVIS A BRIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-21T20:20:46.000Z","date":"2026-09-17","kind":"grant","planned":false,"acquired":true,"price":0,"reported_value":12200,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments over a 12-month period, subject to the Reporting Person's continuous service as of each vesting date."}],"balance_after":12200,"derivative":{"exercise_price":2.13,"expiration_date":"2036-09-16","underlying":"Common Stock","underlying_shares":12200},"source":{"system":"sec-edgar","filing":"0001140361-26-037245","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126037245/form4.xml","form_type":"4"}},{"id":4623220,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":69512,"kind":"person","name":"Kavuru Vimal","position":1,"cik":"0001697184","reported_name":"Kavuru Vimal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-21T20:15:03.000Z","date":"2026-09-17","kind":"grant","planned":false,"acquired":true,"shares":12200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments over a 12-month period, subject to the Reporting Person's continuous service as of each vesting date."}],"balance_after":12200,"derivative":{"exercise_price":2.13,"expiration_date":"2036-09-16","underlying":"Common Stock","underlying_shares":12200},"source":{"system":"sec-edgar","filing":"0001140361-26-037239","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1697184/000114036126037239/form4.xml","form_type":"4"}},{"id":4623207,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":69528,"kind":"person","name":"Kottayil George","position":1,"cik":"0001895357","reported_name":"Kottayil George","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-21T20:13:11.000Z","date":"2026-09-17","kind":"grant","planned":false,"acquired":true,"shares":12200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments over a 12-month period, subject to the Reporting Person's continuous service as of each vesting date."}],"balance_after":12200,"derivative":{"exercise_price":2.13,"expiration_date":"2036-09-16","underlying":"Common Stock","underlying_shares":12200},"source":{"system":"sec-edgar","filing":"0001140361-26-037237","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895357/000114036126037237/form4.xml","form_type":"4"}},{"id":4614515,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":1559,"kind":"organization","name":"Opaleye Management Inc.","position":1,"cik":"0001595855","reported_name":"Opaleye Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2026-09-10T20:05:18.000Z","date":"2026-09-09","kind":"purchase","planned":false,"acquired":true,"shares":5836,"price":2.0899,"value":12196.6564,"ownership":{"direct":false,"nature":"By Opaleye, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.085 to $2.09. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents securities owned directly by Opaleye, L.P. (the \"Fund\"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2775229,"source":{"system":"sec-edgar","filing":"0001493152-26-042152","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1595855/000149315226042152/ownership.xml","form_type":"4"}},{"id":4614514,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":1559,"kind":"organization","name":"Opaleye Management Inc.","position":1,"cik":"0001595855","reported_name":"Opaleye Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2026-09-10T20:05:18.000Z","date":"2026-09-08","kind":"purchase","planned":false,"acquired":true,"shares":9393,"price":2.0972,"value":19698.9996,"ownership":{"direct":false,"nature":"By Opaleye, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.095 to $2.10. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents securities owned directly by Opaleye, L.P. (the \"Fund\"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2769393,"source":{"system":"sec-edgar","filing":"0001493152-26-042152","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1595855/000149315226042152/ownership.xml","form_type":"4"}},{"id":4614368,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":18014,"kind":"person","name":"Kohli Prashant","position":1,"cik":"0001946739","reported_name":"Kohli Prashant","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-10T11:30:38.000Z","date":"2026-09-09","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":2.14,"value":214000.0,"ownership":{"direct":true},"balance_after":121357,"source":{"system":"sec-edgar","filing":"0001140361-26-036125","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946739/000114036126036125/form4.xml","form_type":"4"}},{"id":671020,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":17917,"kind":"person","name":"Kumar Amresh","position":1,"cik":"0001978220","reported_name":"Kumar Amresh","relationship":{"officer":true,"officer_title":"VP Program Management"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:05:18.000Z","date":"2026-08-28","kind":"grant","planned":false,"acquired":true,"shares":35760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest quarterly in substantially equal installments over a three-year period, subject to the Reporting Person's continuous service as of each vesting date, The first 1/12 tranche shall vest immediately upon the grant date with the remaining 11/12 vesting equally over the following 11 quarters starting on the three-month anniversary of the grant date."}],"balance_after":35760,"derivative":{"exercise_price":2.12,"expiration_date":"2036-08-27","underlying":"Common Stock","underlying_shares":35760},"source":{"system":"sec-edgar","filing":"0001140361-26-035318","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126035318/form4.xml","form_type":"4"}},{"id":671368,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":18014,"kind":"person","name":"Kohli Prashant","position":1,"cik":"0001946739","reported_name":"Kohli Prashant","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:05:16.000Z","date":"2026-08-28","kind":"grant","planned":false,"acquired":true,"shares":267160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest quarterly in substantially equal installments over a three-year period, subject to the Reporting Person's continuous service as of each vesting date, The first 1/12 tranche shall vest immediately upon the grant date with the remaining 11/12 vesting equally over the following 11 quarters starting on the three-month anniversary of the grant date."}],"balance_after":267160,"derivative":{"exercise_price":2.12,"expiration_date":"2036-08-27","underlying":"Common Stock","underlying_shares":267160},"source":{"system":"sec-edgar","filing":"0001140361-26-035319","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946739/000114036126035319/form4.xml","form_type":"4"}},{"id":671067,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":17928,"kind":"person","name":"Macdonald R. Loch","position":1,"cik":"0001653008","reported_name":"Macdonald R. Loch","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:05:16.000Z","date":"2026-08-28","kind":"grant","planned":false,"acquired":true,"shares":54690,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest quarterly in substantially equal installments over a three-year period, subject to the Reporting Person's continuous service as of each vesting date, The first 1/12 tranche shall vest immediately upon the grant date with the remaining 11/12 vesting equally over the following 11 quarters starting on the three-month anniversary of the grant date."}],"balance_after":54690,"derivative":{"exercise_price":2.12,"expiration_date":"2036-08-27","underlying":"Common Stock","underlying_shares":54690},"source":{"system":"sec-edgar","filing":"0001140361-26-035317","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1653008/000114036126035317/form4.xml","form_type":"4"}},{"id":671019,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":17916,"kind":"person","name":"DelAversano Robert J","position":1,"cik":"0001728262","reported_name":"DelAversano Robert J","relationship":{"officer":true,"officer_title":"Principal Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:05:15.000Z","date":"2026-08-28","kind":"grant","planned":false,"acquired":true,"shares":33660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest quarterly in substantially equal installments over a three-year period, subject to the Reporting Person's continuous service as of each vesting date, The first 1/12 tranche shall vest immediately upon the grant date with the remaining 11/12 vesting equally over the following 11 quarters starting on the three-month anniversary of the grant date."}],"balance_after":33660,"derivative":{"exercise_price":2.12,"expiration_date":"2036-08-27","underlying":"Common Stock","underlying_shares":33660},"source":{"system":"sec-edgar","filing":"0001140361-26-035316","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126035316/form4.xml","form_type":"4"}},{"id":681265,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":1559,"kind":"organization","name":"Opaleye Management Inc.","position":1,"cik":"0001595855","reported_name":"Opaleye Management Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2026-08-19T11:44:39.000Z","date":"2026-08-14","kind":"purchase","planned":false,"acquired":true,"shares":11608,"price":2.0853,"value":24206.1624,"ownership":{"direct":false,"nature":"By Opaleye, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.05 to $2.09. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents securities owned directly by Opaleye, L.P. (the \"Fund\"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2760000,"source":{"system":"sec-edgar","filing":"0001493152-26-039124","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000149315226039124/ownership.xml","form_type":"4"}},{"id":940925,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":69512,"kind":"person","name":"Kavuru Vimal","position":1,"cik":"0001697184","reported_name":"Kavuru Vimal","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-12T21:01:37.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option vests on the date of grant and the remaining 75% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2026, subject to the Reporting Person's continuous service as of each vesting date."}],"balance_after":10000,"derivative":{"exercise_price":3.8,"expiration_date":"2036-01-08","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001140361-26-000969","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126000969/form4.xml","form_type":"4"}},{"id":940924,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":69511,"kind":"person","name":"NEUGEBOREN EDWARD","position":1,"cik":"0001320873","reported_name":"NEUGEBOREN EDWARD","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-12T21:01:34.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option vests on the date of grant and the remaining 75% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2026, subject to the Reporting Person's continuous service as of each vesting date."}],"balance_after":10000,"derivative":{"exercise_price":3.8,"expiration_date":"2036-01-08","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001140361-26-000967","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126000967/form4.xml","form_type":"4"}},{"id":940923,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":69510,"kind":"person","name":"DAVIS A BRIAN","position":1,"cik":"0001184432","reported_name":"DAVIS A BRIAN","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-12T21:01:33.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option vests on the date of grant and the remaining 75% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2026, subject to the Reporting Person's continuous service as of each vesting date."}],"balance_after":10000,"derivative":{"exercise_price":3.8,"expiration_date":"2036-01-08","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001140361-26-000966","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036126000966/form4.xml","form_type":"4"}},{"id":941143,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":69528,"kind":"person","name":"Kottayil George","position":1,"cik":"0001895357","reported_name":"Kottayil George","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-12T16:01:36.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option vests on the date of grant and the remaining 75% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2026, subject to the Reporting Person's continuous service as of each vesting date."}],"balance_after":10000,"derivative":{"exercise_price":3.8,"expiration_date":"2036-01-08","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001140361-26-000968","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895357/000114036126000968/form4.xml","form_type":"4"}},{"id":1150749,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":69511,"kind":"person","name":"NEUGEBOREN EDWARD","position":1,"cik":"0001320873","reported_name":"NEUGEBOREN EDWARD","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-13T21:21:14.000Z","date":"2025-05-09","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2025, subject to the Reporting Person's continuous service as of each vesting date."}],"balance_after":10000,"derivative":{"exercise_price":2.72,"expiration_date":"2035-05-09","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001140361-25-018696","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036125018696/form4.xml","form_type":"4"}},{"id":1150748,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":69510,"kind":"person","name":"DAVIS A BRIAN","position":1,"cik":"0001184432","reported_name":"DAVIS A BRIAN","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-13T21:21:13.000Z","date":"2025-05-09","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2025, subject to the Reporting Person's continuous service as of each vesting date."}],"balance_after":10000,"derivative":{"exercise_price":2.72,"expiration_date":"2035-05-09","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001140361-25-018695","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036125018695/form4.xml","form_type":"4"}},{"id":1150747,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":69512,"kind":"person","name":"Kavuru Vimal","position":1,"cik":"0001697184","reported_name":"Kavuru Vimal","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-13T21:21:11.000Z","date":"2025-05-09","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2025, subject to the Reporting Person's continuous service as of each vesting date."}],"balance_after":10000,"derivative":{"exercise_price":2.72,"expiration_date":"2035-05-09","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001140361-25-018694","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036125018694/form4.xml","form_type":"4"}},{"id":1151030,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":69528,"kind":"person","name":"Kottayil George","position":1,"cik":"0001895357","reported_name":"Kottayil George","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-13T17:21:16.000Z","date":"2025-05-09","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2025, subject to the Reporting Person's continuous service as of each vesting date."}],"balance_after":10000,"derivative":{"exercise_price":2.72,"expiration_date":"2035-05-09","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001140361-25-018698","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895357/000114036125018698/form4.xml","form_type":"4"}},{"id":1170965,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":17917,"kind":"person","name":"Kumar Amresh","position":1,"cik":"0001978220","reported_name":"Kumar Amresh","relationship":{"officer":true,"officer_title":"VP Program Management"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-17T00:58:53.000Z","date":"2025-04-14","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests quarterly in substantially equal installments over a 3-year period, subject to the Reporting Person's continuous service as of each vesting date."}],"balance_after":30000,"derivative":{"exercise_price":2.08,"expiration_date":"2035-04-14","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001140361-25-014266","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036125014266/form4.xml","form_type":"4"}},{"id":1170995,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":17928,"kind":"person","name":"Macdonald R. Loch","position":1,"cik":"0001653008","reported_name":"Macdonald R. Loch","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-17T00:58:52.000Z","date":"2025-04-14","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests quarterly in substantially equal installments over a 3-year period, subject to the Reporting Person's continuous service as of each vesting date."}],"balance_after":40000,"derivative":{"exercise_price":2.08,"expiration_date":"2035-04-14","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001140361-25-014265","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1653008/000114036125014265/form4.xml","form_type":"4"}},{"id":1170963,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":17916,"kind":"person","name":"DelAversano Robert J","position":1,"cik":"0001728262","reported_name":"DelAversano Robert J","relationship":{"officer":true,"officer_title":"Principal Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-17T00:58:50.000Z","date":"2025-04-14","kind":"grant","planned":false,"acquired":true,"shares":20130,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests quarterly in substantially equal installments over a 3-year period, subject to the Reporting Person's continuous service as of each vesting date."}],"balance_after":20130,"derivative":{"exercise_price":2.08,"expiration_date":"2035-04-14","underlying":"Common Stock","underlying_shares":20130},"source":{"system":"sec-edgar","filing":"0001140361-25-014264","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036125014264/form4.xml","form_type":"4"}},{"id":1171101,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":18014,"kind":"person","name":"Kohli Prashant","position":1,"cik":"0001946739","reported_name":"Kohli Prashant","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-17T00:58:49.000Z","date":"2025-04-14","kind":"grant","planned":false,"acquired":true,"shares":225400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests quarterly in substantially equal installments over a 3-year period, subject to the Reporting Person's continuous service as of each vesting date."}],"balance_after":225400,"derivative":{"exercise_price":2.08,"expiration_date":"2035-04-14","underlying":"Common Stock","underlying_shares":225400},"source":{"system":"sec-edgar","filing":"0001140361-25-014263","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946739/000114036125014263/form4.xml","form_type":"4"}},{"id":1170964,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":80752,"kind":"person","name":"D'Andrea Carrie","position":1,"cik":"0001977969","reported_name":"D'Andrea Carrie","relationship":{"officer":true,"officer_title":"VP Clinical Operations"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-17T00:58:47.000Z","date":"2025-04-14","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests quarterly in substantially equal installments over a 3-year period, subject to the Reporting Person's continuous service as of each vesting date."}],"balance_after":30000,"derivative":{"exercise_price":2.08,"expiration_date":"2035-04-14","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001140361-25-014262","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000114036125014262/form4.xml","form_type":"4"}},{"id":1520583,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":80752,"kind":"person","name":"D'Andrea Carrie","position":1,"cik":"0001977969","reported_name":"D'Andrea Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Clinical Operations"}}],"security":"Stock Options (Right to Buy)","published_at":"2024-05-10T20:11:36.000Z","date":"2024-05-06","kind":"grant","planned":false,"acquired":true,"shares":19740,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This amendment to Form 4 is being filed to amend the signature block in the original Form 4, filed on May 8, 2024, to reflect the correct signatory."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock options granted on 05/06/2024 under the Acasti Pharma Stock Option Plan, which vest quarterly in equal installments over a 36-month period."}],"balance_after":19740,"derivative":{"exercise_price":2.96,"expiration_date":"2034-05-06","underlying":"Class A Common Shares","underlying_shares":19740},"source":{"system":"sec-edgar","filing":"0000950170-24-057822","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000095017024057822/ownership.xml","form_type":"4/A","original_submission_date":"2024-05-08"}},{"id":1520582,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":17917,"kind":"person","name":"Kumar Amresh","position":1,"cik":"0001978220","reported_name":"Kumar Amresh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Program Management"}}],"security":"Stock Options (Right to Buy)","published_at":"2024-05-10T20:07:54.000Z","date":"2024-05-06","kind":"grant","planned":false,"acquired":true,"shares":19740,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This amendment to Form 4 is being filed to amend the signature block in the original Form 4, filed on May 8, 2024, to reflect the correct signatory."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock options granted on 05/06/2024 under the Acasti Pharma Stock Option Plan, which vest quarterly in equal installments over a 36-month period."}],"balance_after":19740,"derivative":{"exercise_price":2.96,"expiration_date":"2034-05-06","underlying":"Class A Common Shares","underlying_shares":19740},"source":{"system":"sec-edgar","filing":"0000950170-24-057811","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000095017024057811/ownership.xml","form_type":"4/A","original_submission_date":"2024-05-08"}},{"id":1523232,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":80752,"kind":"person","name":"D'Andrea Carrie","position":1,"cik":"0001977969","reported_name":"D'Andrea Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Program Management"}}],"security":"Stock Options (Right to Buy)","published_at":"2024-05-08T23:19:39.000Z","date":"2024-05-06","kind":"grant","planned":false,"acquired":true,"shares":19740,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options granted on 05/06/2024 under the Acasti Pharma Stock Option Plan, which vest quarterly in equal installments over a 36-month period."}],"balance_after":19740,"derivative":{"exercise_price":2.96,"expiration_date":"2034-05-06","underlying":"Class A Common Shares","underlying_shares":19740},"source":{"system":"sec-edgar","filing":"0000950170-24-056086","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000095017024056086/ownership.xml","form_type":"4"}},{"id":1523231,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":17917,"kind":"person","name":"Kumar Amresh","position":1,"cik":"0001978220","reported_name":"Kumar Amresh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Clinical Operations"}}],"security":"Stock Options (Right to Buy)","published_at":"2024-05-08T23:19:20.000Z","date":"2024-05-06","kind":"grant","planned":false,"acquired":true,"shares":19740,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options granted on 05/06/2024 under the Acasti Pharma Stock Option Plan, which vest quarterly in equal installments over a 36-month period."}],"balance_after":19740,"derivative":{"exercise_price":2.96,"expiration_date":"2034-05-06","underlying":"Class A Common Shares","underlying_shares":19740},"source":{"system":"sec-edgar","filing":"0000950170-24-056084","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000095017024056084/ownership.xml","form_type":"4"}},{"id":1523296,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":17928,"kind":"person","name":"Macdonald R. Loch","position":1,"cik":"0001653008","reported_name":"Macdonald R. Loch","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2024-05-08T23:19:03.000Z","date":"2024-05-06","kind":"grant","planned":false,"acquired":true,"shares":25380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options granted on 05/06/2024 under the Acasti Pharma Stock Option Plan, which vest quarterly in equal installments over a 36-month period."}],"balance_after":25380,"derivative":{"exercise_price":2.96,"expiration_date":"2034-05-06","underlying":"Class A Common Shares","underlying_shares":25380},"source":{"system":"sec-edgar","filing":"0000950170-24-056083","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1653008/000095017024056083/ownership.xml","form_type":"4"}},{"id":1523230,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":17916,"kind":"person","name":"DelAversano Robert J","position":1,"cik":"0001728262","reported_name":"DelAversano Robert J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Financial Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2024-05-08T23:18:46.000Z","date":"2024-05-06","kind":"grant","planned":false,"acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options granted on 05/06/2024 under the Acasti Pharma Stock Option Plan, which vest quarterly in equal installments over a 36-month period."}],"balance_after":4500,"derivative":{"exercise_price":2.96,"expiration_date":"2034-05-06","underlying":"Class A Common Shares","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0000950170-24-056082","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000095017024056082/ownership.xml","form_type":"4"}},{"id":1523510,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":18014,"kind":"person","name":"Kohli Prashant","position":1,"cik":"0001946739","reported_name":"Kohli Prashant","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2024-05-08T23:18:18.000Z","date":"2024-05-06","kind":"grant","planned":false,"acquired":true,"shares":128770,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options granted on 05/06/2024 under the Acasti Pharma Stock Option Plan, which vest quarterly in equal installments over a 36-month period."}],"balance_after":128770,"derivative":{"exercise_price":2.96,"expiration_date":"2034-05-06","underlying":"Class A Common Shares","underlying_shares":128770},"source":{"system":"sec-edgar","filing":"0000950170-24-056081","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946739/000095017024056081/ownership.xml","form_type":"4"}},{"id":1703299,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":69512,"kind":"person","name":"Kavuru Vimal","position":1,"cik":"0001697184","reported_name":"Kavuru Vimal","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-20T21:08:54.000Z","date":"2023-12-19","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options granted on 12/19/2023 under the Acasti Pharma Stock Option Plan, which vest in equal monthly installments over a period of 12 months, provided that 3/12 of the options shall be deemed to have vested upon the date of grant."}],"balance_after":10000,"derivative":{"exercise_price":2.125,"expiration_date":"2033-12-19","underlying":"Class A Common Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000950170-23-071885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023071885/ownership.xml","form_type":"4"}},{"id":1703284,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":69511,"kind":"person","name":"NEUGEBOREN EDWARD","position":1,"cik":"0001320873","reported_name":"NEUGEBOREN EDWARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-20T21:06:54.000Z","date":"2023-12-19","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options granted on 12/19/2023 under the Acasti Pharma Stock Option Plan, which 10,000 shares vest in equal monthly installments over a period of 12 months (provided that 3/12 of the options shall be deemed to have vested upon the date of grant), and 12,500 shares vest in equal quarterly installments over a period of 18 months (Provided that 1/6 of the options shall be deemed to have vested upon the date of grant)."}],"balance_after":22500,"derivative":{"exercise_price":2.125,"expiration_date":"2033-12-19","underlying":"Class A Common Shares","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000950170-23-071879","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023071879/ownership.xml","form_type":"4"}},{"id":1703283,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":69510,"kind":"person","name":"DAVIS A BRIAN","position":1,"cik":"0001184432","reported_name":"DAVIS A BRIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-20T21:06:02.000Z","date":"2023-12-19","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options granted on 12/19/2023 under the Acasti Pharma Stock Option Plan, which 10,000 shares vest in equal monthly installments over a period of 12 months (provided that 3/12 of the options shall be deemed to have vested upon the date of grant), and 12,500 shares vest in equal quarterly installments over a period of 18 months (Provided that 1/6 of the options shall be deemed to have vested upon the date of grant)."}],"balance_after":22500,"derivative":{"exercise_price":2.125,"expiration_date":"2033-12-19","underlying":"Class A Common Shares","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000950170-23-071877","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023071877/ownership.xml","form_type":"4"}},{"id":1703497,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":18014,"kind":"person","name":"Kohli Prashant","position":1,"cik":"0001946739","reported_name":"Kohli Prashant","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-20T21:05:27.000Z","date":"2023-12-19","kind":"grant","planned":false,"acquired":true,"shares":41668,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options granted on 12/19/2023 under the Acasti Pharma Stock Option Plan, which fully vested upon grant."}],"balance_after":41668,"derivative":{"exercise_price":2.125,"expiration_date":"2033-12-19","underlying":"Class A Common Shares","underlying_shares":41668},"source":{"system":"sec-edgar","filing":"0000950170-23-071875","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946739/000095017023071875/ownership.xml","form_type":"4"}},{"id":1703488,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":69528,"kind":"person","name":"Kottayil George","position":1,"cik":"0001895357","reported_name":"Kottayil George","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-20T16:08:23.000Z","date":"2023-12-19","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options granted on 12/19/2023 under the Acasti Pharma Stock Option Plan, which 10,000 shares vest in equal monthly installments over a period of 12 months (provided that 3/12 of the options shall be deemed to have vested upon the date of grant), and 12,500 shares vest in equal quarterly installments over a period of 18 months (Provided that 1/6 of the options shall be deemed to have vested upon the date of grant)."}],"balance_after":22500,"derivative":{"exercise_price":2.125,"expiration_date":"2033-12-19","underlying":"Class A Common Shares","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000950170-23-071883","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895357/000095017023071883/ownership.xml","form_type":"4"}},{"id":1772586,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":69512,"kind":"person","name":"Kavuru Vimal","position":1,"cik":"0001697184","reported_name":"Kavuru Vimal","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Warrants (right to buy)","published_at":"2023-09-27T23:46:45.000Z","date":"2023-09-25","kind":"purchase","planned":false,"acquired":true,"shares":422732,"price":0.125,"value":52841.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Common Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Common Warrants until such time as the holder and certain other related parties, would not beneficially own after any such exercise more than 19.99% of the then issued and outstanding common shares of the Company (the \"Blocker\"). Due to the Blocker, the Common Warrants beneficially owned indirectly by the holder are only currently partially exercisable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Common Warrants will expire on the earlier of (i) the 60th day after the date of the acceptance by the U.S. Food and Drug Administration of a New Drug Application for the Company's product candidate GTX-104 or (ii) September 25, 2028."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Shore Pharma LLC, of which Vimal Kavuru is the sole member."}],"balance_after":422732,"derivative":{"exercise_price":3.003,"exercise_date":"2023-09-25","underlying":"Common Shares","underlying_shares":422732},"source":{"system":"sec-edgar","filing":"0001062993-23-018542","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000106299323018542/form4.xml","form_type":"4"}},{"id":1772585,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":69512,"kind":"person","name":"Kavuru Vimal","position":1,"cik":"0001697184","reported_name":"Kavuru Vimal","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2023-09-27T23:46:45.000Z","date":"2023-09-25","kind":"purchase","planned":false,"acquired":true,"shares":676371,"price":1.848,"value":1249933.608,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These indirect holdings have been adjusted to give effect to the Company's 1-for-6 reverse stock split, effective July 10, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Shore Pharma LLC, of which Vimal Kavuru is the sole member."}],"balance_after":1188076,"source":{"system":"sec-edgar","filing":"0001062993-23-018542","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000106299323018542/form4.xml","form_type":"4"}},{"id":1789349,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":109996,"kind":"person","name":"Olds Donald","position":1,"cik":"0001807762","reported_name":"Olds Donald","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2023-09-05T15:54:48.000Z","date":"2023-08-31","kind":"purchase","planned":false,"acquired":true,"shares":381,"price":2.05,"value":781.05,"ownership":{"direct":true},"balance_after":381,"source":{"system":"sec-edgar","filing":"0001062993-23-017516","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807762/000106299323017516/form4.xml","form_type":"4"}},{"id":1827757,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":69512,"kind":"person","name":"Kavuru Vimal","position":1,"cik":"0001697184","reported_name":"Kavuru Vimal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-07-18T20:36:40.000Z","date":"2023-07-14","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options granted on 07/14/2023 under the Acasti Pharma Stock Option Plan, which vest and become exercisable in equal monthly installments over a period of 12 months."}],"balance_after":12500,"derivative":{"exercise_price":2.64,"expiration_date":"2033-07-14","underlying":"Class A Common Shares","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001062993-23-014999","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000106299323014999/form4.xml","form_type":"4"}},{"id":1827806,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":17928,"kind":"person","name":"Macdonald R. Loch","position":1,"cik":"0001653008","reported_name":"Macdonald R. Loch","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-07-18T20:34:18.000Z","date":"2023-07-14","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options granted on 07/14/2023 under the Acasti Pharma Stock Option Plan, which vest and become exercisable in equal quarterly installments over a period of 36 months."}],"balance_after":60000,"derivative":{"exercise_price":2.64,"expiration_date":"2033-07-14","underlying":"Class A Common Shares","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001062993-23-014997","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1653008/000106299323014997/form4.xml","form_type":"4"}},{"id":1827756,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":80752,"kind":"person","name":"D'Andrea Carrie","position":1,"cik":"0001977969","reported_name":"D'Andrea Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Clinical Operations"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-07-18T20:32:53.000Z","date":"2023-07-14","kind":"grant","planned":false,"acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options granted on 07/14/2023 under the Acasti Pharma Stock Option Plan, which vest and become exercisable in equal quarterly installments over a period of 36 months."}],"balance_after":42000,"derivative":{"exercise_price":2.64,"expiration_date":"2033-07-14","underlying":"Class A Common Shares","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001062993-23-014996","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000106299323014996/form4.xml","form_type":"4"}},{"id":1827755,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":17917,"kind":"person","name":"Kumar Amresh","position":1,"cik":"0001978220","reported_name":"Kumar Amresh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP Program Management"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-07-18T20:28:51.000Z","date":"2023-07-14","kind":"grant","planned":false,"acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options granted on 07/14/2023 under the Acasti Pharma Stock Option Plan, which vest and become exercisable in equal quarterly installments over a period of 36 months."}],"balance_after":42000,"derivative":{"exercise_price":2.64,"expiration_date":"2033-07-14","underlying":"Class A Common Shares","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001062993-23-014995","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000106299323014995/form4.xml","form_type":"4"}},{"id":1827966,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":18014,"kind":"person","name":"Kohli Prashant","position":1,"cik":"0001946739","reported_name":"Kohli Prashant","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-07-18T20:26:07.000Z","date":"2023-07-14","kind":"grant","planned":false,"acquired":true,"shares":208334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options granted on 07/14/2023 under the Acasti Pharma Stock Option Plan, which vest and become exercisable in equal quarterly installments over a period of 36 months."}],"balance_after":208334,"derivative":{"exercise_price":2.64,"expiration_date":"2033-07-14","underlying":"Class A Common Shares","underlying_shares":208334},"source":{"system":"sec-edgar","filing":"0001062993-23-014994","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1946739/000106299323014994/form4.xml","form_type":"4"}},{"id":1827902,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":107895,"kind":"person","name":"Derby Michael","position":1,"cik":"0001809613","reported_name":"Derby Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-07-18T16:37:14.000Z","date":"2023-07-14","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options granted on 07/14/2023 under the Acasti Pharma Stock Option Plan, which vest and become exercisable in equal monthly installments over a period of 12 months."}],"balance_after":12500,"derivative":{"exercise_price":2.64,"expiration_date":"2033-07-14","underlying":"Class A Common Shares","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001062993-23-015000","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809613/000106299323015000/form4.xml","form_type":"4"}},{"id":1827898,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":109996,"kind":"person","name":"Olds Donald","position":1,"cik":"0001807762","reported_name":"Olds Donald","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-07-18T16:36:00.000Z","date":"2023-07-14","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options granted on 07/14/2023 under the Acasti Pharma Stock Option Plan, which vest and become exercisable in equal monthly installments over a period of 12 months."}],"balance_after":12500,"derivative":{"exercise_price":2.64,"expiration_date":"2033-07-14","underlying":"Class A Common Shares","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001062993-23-014998","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807762/000106299323014998/form4.xml","form_type":"4"}},{"id":2148645,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":69512,"kind":"person","name":"Kavuru Vimal","position":1,"cik":"0001697184","reported_name":"Kavuru Vimal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-09-30T20:21:17.000Z","date":"2022-09-28","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Based on conversion of exercise price of C$0.80 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7321 on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock options granted on 09/28/2022 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months."}],"balance_after":45000,"derivative":{"exercise_price":0.59,"expiration_date":"2032-09-28","underlying":"Class A Common Shares","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001171843-22-006335","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000117184322006335/ownership.xml","form_type":"4"}},{"id":2148644,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":12624,"kind":"person","name":"Canan John","position":1,"cik":"0001374366","reported_name":"Canan John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-09-30T20:19:08.000Z","date":"2022-09-28","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Based on conversion of exercise price of C$0.80 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7321 on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock options granted on 09/28/2022 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months."}],"balance_after":45000,"derivative":{"exercise_price":0.59,"expiration_date":"2032-09-28","underlying":"Class A Common Shares","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001171843-22-006333","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000117184322006333/ownership.xml","form_type":"4"}},{"id":2148741,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":109996,"kind":"person","name":"Olds Donald","position":1,"cik":"0001807762","reported_name":"Olds Donald","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-09-30T16:20:34.000Z","date":"2022-09-28","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Based on conversion of exercise price of C$0.80 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7321 on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock options granted on 09/28/2022 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months."}],"balance_after":45000,"derivative":{"exercise_price":0.59,"expiration_date":"2032-09-28","underlying":"Class A Common Shares","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001171843-22-006334","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807762/000117184322006334/ownership.xml","form_type":"4"}},{"id":2148742,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":107895,"kind":"person","name":"Derby Michael","position":1,"cik":"0001809613","reported_name":"Derby Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-09-30T16:18:16.000Z","date":"2022-09-28","kind":"grant","acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Based on conversion of exercise price of C$0.80 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7321 on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock options granted on 09/28/2022 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months."}],"balance_after":85000,"derivative":{"exercise_price":0.59,"expiration_date":"2032-09-28","underlying":"Class A Common Shares","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001171843-22-006332","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809613/000117184322006332/ownership.xml","form_type":"4"}},{"id":2223000,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":125902,"kind":"person","name":"Ford Brian D.","position":1,"cik":"0001825758","reported_name":"Ford Brian D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-06-23T20:34:07.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":165000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Based on conversion of exercise price of C$1.15 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7727 on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock options granted on 06/22/2022 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months."}],"balance_after":165000,"derivative":{"exercise_price":0.89,"expiration_date":"2032-06-22","underlying":"Class A Common Shares","underlying_shares":165000},"source":{"system":"sec-edgar","filing":"0001171843-22-004515","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000117184322004515/ownership.xml","form_type":"4"}},{"id":2223454,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":125938,"kind":"person","name":"Lemieux Pierre","position":1,"cik":"0001807098","reported_name":"Lemieux Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, Canada & CSO"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-06-23T16:34:40.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":165000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Based on conversion of exercise price of C$1.15 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7727 on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock options granted on 06/22/2022 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months."}],"balance_after":165000,"derivative":{"exercise_price":0.89,"expiration_date":"2032-06-22","underlying":"Class A Common Shares","underlying_shares":165000},"source":{"system":"sec-edgar","filing":"0001171843-22-004517","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807098/000117184322004517/ownership.xml","form_type":"4"}},{"id":2223189,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":69528,"kind":"person","name":"Kottayil George","position":1,"cik":"0001895357","reported_name":"Kottayil George","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, US"}}],"security":"06/22/2022","published_at":"2022-06-23T16:34:16.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Based on conversion of exercise price of C$1.15 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7727 on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock options granted on 06/22/2022 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months."}],"balance_after":50000,"derivative":{"exercise_price":0.89,"expiration_date":"2032-06-22","underlying":"Class A Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001171843-22-004516","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895357/000117184322004516/ownership.xml","form_type":"4"}},{"id":2223129,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":125914,"kind":"person","name":"D'Alvise Janelle","position":1,"cik":"0001807412","reported_name":"D'Alvise Janelle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-06-23T16:33:34.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":560000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Based on conversion of exercise price of C$1.15 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7727 on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock options granted on 06/22/2022 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months."}],"balance_after":560000,"derivative":{"exercise_price":0.89,"expiration_date":"2032-06-22","underlying":"Class A Common Shares","underlying_shares":560000},"source":{"system":"sec-edgar","filing":"0001171843-22-004514","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807412/000117184322004514/ownership.xml","form_type":"4"}},{"id":2510497,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":69512,"kind":"person","name":"Kavuru Vimal","position":1,"cik":"0001697184","reported_name":"Kavuru Vimal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-11-16T21:20:09.000Z","date":"2021-11-12","kind":"grant","acquired":true,"shares":42100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Based on conversion of exercise price of C$2.05 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7959 on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock options granted on 11/12/2021 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable with respect to 25% of the shares every three months."}],"balance_after":42100,"derivative":{"exercise_price":1.63,"expiration_date":"2031-11-12","underlying":"Class A Common Shares","underlying_shares":42100},"source":{"system":"sec-edgar","filing":"0001171843-21-008009","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000117184321008009/ownership.xml","form_type":"4"}},{"id":2510496,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":125902,"kind":"person","name":"Ford Brian D.","position":1,"cik":"0001825758","reported_name":"Ford Brian D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Options (Right to Buy)","published_at":"2021-11-16T21:18:39.000Z","date":"2021-11-12","kind":"grant","acquired":true,"shares":287900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Based on conversion of exercise price of C$2.05 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7959 on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock options granted on 11/12/2021 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months."}],"balance_after":287900,"derivative":{"exercise_price":1.63,"expiration_date":"2031-11-12","underlying":"Class A Common Shares","underlying_shares":287900},"source":{"system":"sec-edgar","filing":"0001171843-21-008007","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000117184321008007/ownership.xml","form_type":"4"}},{"id":2510495,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":12624,"kind":"person","name":"Canan John","position":1,"cik":"0001374366","reported_name":"Canan John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-11-16T21:16:51.000Z","date":"2021-11-12","kind":"grant","acquired":true,"shares":42100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Based on conversion of exercise price of C$2.05 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7959 on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock options granted on 11/12/2021 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable with respect to 25% of the shares every three months."}],"balance_after":42100,"derivative":{"exercise_price":1.63,"expiration_date":"2031-11-12","underlying":"Class A Common Shares","underlying_shares":42100},"source":{"system":"sec-edgar","filing":"0001171843-21-008004","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444192/000117184321008004/ownership.xml","form_type":"4"}},{"id":2510869,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":109996,"kind":"person","name":"Olds Donald","position":1,"cik":"0001807762","reported_name":"Olds Donald","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-11-16T16:21:04.000Z","date":"2021-11-12","kind":"grant","acquired":true,"shares":42100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Based on conversion of exercise price of C$2.05 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7959 on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock options granted on 11/12/2021 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable with respect to 25% of the shares every three months."}],"balance_after":42100,"derivative":{"exercise_price":1.63,"expiration_date":"2031-11-12","underlying":"Class A Common Shares","underlying_shares":42100},"source":{"system":"sec-edgar","filing":"0001171843-21-008011","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807762/000117184321008011/ownership.xml","form_type":"4"}},{"id":2511700,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":125938,"kind":"person","name":"Lemieux Pierre","position":1,"cik":"0001807098","reported_name":"Lemieux Pierre","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, Canada & CSO"}}],"security":"Stock Options (Right to Buy)","published_at":"2021-11-16T16:20:48.000Z","date":"2021-11-12","kind":"grant","acquired":true,"shares":287900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Based on conversion of exercise price of C$2.05 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7959 on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock options granted on 11/12/2021 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months."}],"balance_after":287900,"derivative":{"exercise_price":1.63,"expiration_date":"2031-11-12","underlying":"Class A Common Shares","underlying_shares":287900},"source":{"system":"sec-edgar","filing":"0001171843-21-008010","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807098/000117184321008010/ownership.xml","form_type":"4"}},{"id":2511644,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":133491,"kind":"person","name":"HASELTINE WILLIAM A","position":1,"cik":"0000938807","reported_name":"HASELTINE WILLIAM A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-11-16T16:19:31.000Z","date":"2021-11-12","kind":"grant","acquired":true,"shares":42100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Based on conversion of exercise price of C$2.05 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7959 on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock options granted on 11/12/2021 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable with respect to 25% of the shares every three months."}],"balance_after":42100,"derivative":{"exercise_price":1.63,"expiration_date":"2031-11-12","underlying":"Class A Common Shares","underlying_shares":42100},"source":{"system":"sec-edgar","filing":"0001171843-21-008008","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/938807/000117184321008008/ownership.xml","form_type":"4"}},{"id":2510868,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":125914,"kind":"person","name":"D'Alvise Janelle","position":1,"cik":"0001807412","reported_name":"D'Alvise Janelle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2021-11-16T16:18:06.000Z","date":"2021-11-12","kind":"grant","acquired":true,"shares":655500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Based on conversion of exercise price of C$2.05 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7959 on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock options granted on 11/12/2021 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months."}],"balance_after":655500,"derivative":{"exercise_price":1.63,"expiration_date":"2031-11-12","underlying":"Class A Common Shares","underlying_shares":655500},"source":{"system":"sec-edgar","filing":"0001171843-21-008006","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807412/000117184321008006/ownership.xml","form_type":"4"}},{"id":2510867,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":133456,"kind":"person","name":"Carter Roderick Noel","position":1,"cik":"0001807558","reported_name":"Carter Roderick Noel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2021-11-16T16:17:28.000Z","date":"2021-11-12","kind":"grant","acquired":true,"shares":42100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Based on conversion of exercise price of C$2.05 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7959 on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock options granted on 11/12/2021 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable with respect to 25% of the shares every three months."}],"balance_after":42100,"derivative":{"exercise_price":1.63,"expiration_date":"2031-11-12","underlying":"Class A Common Shares","underlying_shares":42100},"source":{"system":"sec-edgar","filing":"0001171843-21-008005","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807558/000117184321008005/ownership.xml","form_type":"4"}}]}